Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has provided an announcement.
Clarity Pharmaceuticals Ltd. has received Fast Track Designation from the US FDA for its Cu-67 SAR-bisPSMA product aimed at treating metastatic castration-resistant prostate cancer. This designation is a significant milestone, allowing Clarity to expedite the regulatory review process, potentially transforming prostate cancer treatment by addressing unmet medical needs and offering innovative therapeutic options. Positive preliminary results from the SECuRE study indicate the treatment’s efficacy in reducing PSA levels in heavily pre-treated patients, highlighting its potential in changing the prostate cancer treatment landscape.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd. is a clinical-stage radiopharmaceutical company focused on developing next-generation products to improve cancer treatment outcomes for both children and adults. It operates in the healthcare industry, specifically targeting cancer diagnostics and therapeutics, with a particular focus on prostate cancer.
YTD Price Performance: -18.47%
Average Trading Volume: 1,721,570
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$1.09B
See more insights into CU6 stock on TipRanks’ Stock Analysis page.
